<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077592</url>
  </required_header>
  <id_info>
    <org_study_id>POV-2021</org_study_id>
    <nct_id>NCT05077592</nct_id>
  </id_info>
  <brief_title>Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections</brief_title>
  <official_title>Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized controlled trail to To assess the efficacy of povidone-iodine wash before wound&#xD;
      closure in preventing surgical site infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical site infections are post-operative infections of the incision or organ or space that&#xD;
      was included in the surgical field. Incisional surgical site infections (SSIs) are a growing&#xD;
      healthcare challenge.&#xD;
&#xD;
      Currently, up to 10% of surgical procedures may be complicated by an SSI [3]. Not only do&#xD;
      SSIs lead to worse patient outcomes, but they also account for a large proportion of&#xD;
      healthcare expenditure.&#xD;
&#xD;
      In the United Kingdom alone, SSIs are estimated to cost the National Health Service 1 billion&#xD;
      pounds annually.&#xD;
&#xD;
      The problem is further compounded in low- and middle-income countries (LMICs) where the&#xD;
      prevalence of antibiotic-resistant infections is increasing, and national healthcare budgets&#xD;
      are strained.&#xD;
&#xD;
      In fact, SSIs are estimated to account for additional costs of up to $30,000 in LMICs.&#xD;
&#xD;
      The global crisis of drug-resistant bacteria has further highlighted the need for more&#xD;
      effective perioperative preventive strategies to minimize healthcare-associated resistant&#xD;
      infections.&#xD;
&#xD;
      Optimal surgical antisepsis is critical in reducing the incidence of SSIs, and therefore in&#xD;
      reducing the use of postoperative antibiotics.&#xD;
&#xD;
      Recently, there has been a renewed interest in using povidone-iodine (PVI) intraoperative&#xD;
      wound irrigation to achieve this goal. The choice of PVI is especially suitable for LMICs&#xD;
      where the availability of chlorhexidine preparations may be limited by scarce resources.&#xD;
&#xD;
      A possible adjunctive role of pre-wound closure PVI irrigation in reducing incisional SSIs is&#xD;
      still unclear.&#xD;
&#xD;
      A meta-analysis by López-Cano et al. analyzed data of 7,601 patients and found a reduction in&#xD;
      overall SSI rate. However, the heterogeneity and uncertain quality of most studies limited&#xD;
      the synthesis of conclusive evidence.&#xD;
&#xD;
      The possible benefits of irrigating the surface of an open incision include local&#xD;
      antimicrobial effect, physical removal of debris and dilution of contamination. Recent&#xD;
      guidelines have all emphasized the lack of sufficient evidence on intraoperative use of PVI.&#xD;
&#xD;
      The investigators aim to conduct a randomized controlled trial in Ain Shams University&#xD;
      Hospitals to compare the effect of adding PVI wash prior to skin closure to direct wound&#xD;
      closure on reducing the rates of SSIs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2021</start_date>
  <completion_date type="Anticipated">January 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>A statistician not directly involved in the study or analysis will prepare a computer-generated randomization sequence. No blocking will be used. The sequence will be provided to the trialists in the form of serially numbered opaque envelopes containing details of either the intervention or the control and a random identifier.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical Site Infection Incidence</measure>
    <time_frame>30 days</time_frame>
    <description>Using the CDC Checklist for Superficial and deep Surgical site infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity and mortality</measure>
    <time_frame>30 Days</time_frame>
    <description>Using the Clavien-Dindo classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 Days</time_frame>
    <description>in days using the hospital records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission and reoperations related to Surgical site infection</measure>
    <time_frame>30 Days</time_frame>
    <description>Using the hospital records, Number of reoperations and readmissions due to surgical site infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>30 Days</time_frame>
    <description>Using qSOFA and SOFA score. such as Sepsis, septic shock, multiple-organ dysfunction syndrome, wound dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiology culture and sensitivity results</measure>
    <time_frame>30 Days</time_frame>
    <description>A microbiology report that contains the exact pathogen strain and antibiotic sensitivity report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local adverse events for povidone-iodine application</measure>
    <time_frame>30 Days</time_frame>
    <description>Symptoms and sings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>30 Days</time_frame>
    <description>In terms of extra hospital stay days and readmission days costs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Surgical Site Infection</condition>
  <condition>Surgical Wound Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Direct Wound closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The use of 10% surgical povidone iodine to wash the wound directly after fascial closure and before wound closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% Povidone Iodine</intervention_name>
    <description>Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>betadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years old)&#xD;
&#xD;
          -  Open and minimally invasive surgeries&#xD;
&#xD;
          -  Emergency (any unplanned admission) and elective (planned admission) surgical&#xD;
             procedures&#xD;
&#xD;
          -  Clean, Clean-Contaminated, Contaminated, Dirty wounds&#xD;
&#xD;
          -  Inclusion surgery list according to Current Procedural Terminology (CPT) National&#xD;
             Healthcare Safety Network (NHSN) operative procedure code mapping&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Povidone-iodine allergy&#xD;
&#xD;
          -  Surgeries for infected wounds.&#xD;
&#xD;
          -  Exclusion surgery list according to Current Procedural Terminology (CPT) National&#xD;
             Healthcare Safety Network (NHSN) operative procedure code mapping.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed AbdelGhany, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdurrahman Abdelzaher</last_name>
    <phone>+201126857234</phone>
    <email>a.t.abdelzaher@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emad Alazab</last_name>
    <phone>201063705669</phone>
    <email>emp14.emad.e.alazab@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waleed AbdelGhany, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Seif Tarek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ibrahim El Garhy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Bahaa, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reda Abdelttawab Essa, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salma Ramadan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Walid Ahmed Abdel-Ghany</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT05077592/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT05077592/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

